ISRCTN83602901已完成不适用
A randomized, double-blind, parallel study to compare the relative absorption of UltraSOL Curcumin and Curcumin reference product
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Normal healthy individuals
- •2. Age 18-55
- •3. Males and females
- •4. Must be able to perform required testing
- •5. Participants agreed to sign an informed consent form
排除标准
- •1. Pregnancy
- •2. Use of prescription medications
- •3. Gastrointestinal conditions
- •4. Diabetics
- •5. Alcohol and/or substance abuse history, and/or allergies to turmeric or curcumin
- •6. Subjects consuming any foods or supplements containing curcumin
研究者
相似试验
进行中（未招募）
不适用
A randomized, double-blind, parallel group study of the safetyand prevention of structural joint damage during treatment withMRA versus placebo, in combination with methotrexate, inpatients with moderate to severe active rheumatoid arthritis.Rheumatoid arthritisEUCTR2004-003733-14-DKF Hoffmann La-Roche Ltd.1,170
进行中（未招募）
1 期
A study investigating whether tocilizumab (study drug) prevents joint damage, and how safe it is, in patients with moderate to severe rheumatoid arthritis randomly divided to groups receiving treatment with tocilizumab and methotrexate or methotrexate and placebo.Rheumatoid ArthritisEUCTR2004-003733-14-FIF. Hoffmann La-Roche Ltd.1,170
进行中（未招募）
不适用
A global study to investigate the safety and effect on clinical outcome of tocilizumab given subcutaneously versus tocilizumab given intravenously, in combination with traditional disease-modifying anti-rheumatic drugs (DMARDs), in patients with moderate to severe active rheumatoid arthritis.MedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid arthritisEUCTR2010-018375-22-LTF. Hoffmann-La Roche Ltd1,200
进行中（未招募）
不适用
A randomized, double-blind, parallel group study of the safety and prevention of structural joint damage during treatment with MRA versus placebo, in combination with methotrexate, in patients with moderate to severe active rheumatoid arthritis.active rheumatoid arthritisMedDRA version: 6.1Level: PTClassification code 10039073EUCTR2004-003733-14-ITROCHE1,170
进行中（未招募）
不适用
A global study to investigate the safety and effect on clinical outcome of tocilizumab given subcutaneously versus tocilizumab given intravenously, in combination with traditional disease-modifying anti-rheumatic drugs (DMARDs), in patients with moderate to severe active rheumatoid arthritis.MedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid arthritisEUCTR2010-018375-22-BGF. Hoffmann-La Roche Ltd1,200